BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20658219)

  • 1. IgG-associated immune thrombocytopenia in Waldenström macroglobulinemia.
    Nakazaki K; Hangaishi A; Nakamura F; Hosoi M; Imai Y; Takahashi T; Nannya Y; Kurokawa M
    Int J Hematol; 2010 Sep; 92(2):360-3. PubMed ID: 20658219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
    Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient.
    Mohammad RM; Aboukameel A; Nabha S; Ibrahim D; Al-Katib A
    J Drug Target; 2002 Aug; 10(5):405-10. PubMed ID: 12442811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waldenström macroglobulinemia: my way.
    Gertz M
    Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful treatment with rituximab and romiplostim for thrombocytopenia associated with Waldenström's macroglobulinemia initially presenting as Evans syndrome].
    Nozaki Y; Koshiishi M; Sueki Y; Kawashima I; Yamamoto T; Nakajima K; Mitsumori T; Kirito K
    Rinsho Ketsueki; 2015 Mar; 56(3):317-22. PubMed ID: 25876786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune thrombocytopenia in Waldenström's macroglobulinemia.
    Owen RG; Lubenko A; Savage J; Parapia LA; Jack AS; Morgan GJ
    Am J Hematol; 2001 Feb; 66(2):116-9. PubMed ID: 11421289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agranulocytosis Associated with Waldenström Macroglobulinemia.
    Vaxman I; Shepshelovich D; Hayman L; Raanani P; Lahav M
    Acta Haematol; 2018; 140(1):42-45. PubMed ID: 30114687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
    Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M
    J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2015 Apr; 90(4):346-54. PubMed ID: 25808108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2011 May; 86(5):411-6. PubMed ID: 21523800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
    Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
    Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2012 May; 87(5):503-10. PubMed ID: 22508368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunobullous dermatosis associated with Waldenström macroglobulinaemia treated with rituximab.
    Chattopadhyay M; Rytina E; Dada M; Bhogal BS; Groves R; Handfield-Jones S
    Clin Exp Dermatol; 2013 Dec; 38(8):866-9. PubMed ID: 23782150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 44-Year-Old Man with Waldenstrom Macroglobulinemia and Bilateral Maxillary Sinusitis.
    Trianto HB; Wardhani SO
    Acta Med Indones; 2016 Jul; 48(3):221-227. PubMed ID: 27840358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia.
    Kaufman M; Limaye SA; Driscoll N; Johnson C; Caramanica A; Lebowicz Y; Patel D; Kohn N; Rai K
    Leuk Lymphoma; 2009 Jun; 50(6):892-9. PubMed ID: 19391041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
    Ise M; Sakai C; Kumagai K
    Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of cryoglobulinemic glomerulonephritis derived from Waldenström's macroglobulinemia by rituximab-CHOP and tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
    Kawano N; Ikeda N; Yoshida S; Sugio Y; Yamashita K; Uezono S; Hayashi T; Hara S; Makino S; Shimoda K; Ueda A
    Int J Hematol; 2010 Sep; 92(2):391-7. PubMed ID: 20686877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Kanan S; Sheehy P; Chuma S; Xu L; Cao Y; Yang G; Liu X; Patterson CJ; Warren D; Hunter ZR; Turnbull B; Ghobrial IM; Castillo JJ
    Blood; 2014 Jul; 124(4):503-10. PubMed ID: 24859363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia.
    Maki N; Demitsu T; Umemoto N; Nagashima K; Nakamura T; Kakurai M; Nakamura S; Yamada T; Ishii N; Hashimoto T
    J Dermatol; 2016 May; 43(5):571-4. PubMed ID: 26507447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.